Abstract
This month’s industry update covers the period 16 October–15 November 2010. A common feature of this time-frame were the number of deals involving novel technologies for actively targeted therapeutics (Wilex and Heidelberg; Algeta and Lumiphore; Boehringer Ingelheim and MacroGenics; Access Pharmaceuticals and undisclosed partner) illustrating the level of sophistication and diversity in approach that is developing in this area. Rare diseases were also a focus with GlaxoSmithKline joining forces with Fondazione Telethon and Fondazione San Raffaele to develop gene therapy for rare genetic diseases and the CHDI Foundation agreeing to provide funding for a novel silencing ribonucleic acid device combination being co-developed by Alnylam and Medtronic for the treatment of Huntingdon’s disease. As ever, the information is mainly taken from drug-delivery websites and press releases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
